The natural history of multiple sclerosis: A geographically based study. 7. Progressvie-relapsing and relapsing-progressive multiple sclerosis: A re-evaluation

Brain

Volumn 122, Issue 10, 1999, Pages 1941-1949

  Kremenchutzky, M ^a   Cottrell, D ^a   Rice, G ^a   Hader, W ^a   Baskerville, J ^a   Koopman, W ^a   Ebers, G C ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

Progressive relapsing multiple sclerosis; Relapsing progressive multiple sclerosis

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; DISABILITY; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; REMISSION;

ADULT; AGE OF ONSET; CANADA; COHORT STUDIES; DEMOGRAPHY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PROGNOSIS; RECURRENCE; REMISSION, SPONTANEOUS; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE; TERMINOLOGY; TIME FACTORS;

EID: 0032881051     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/122.10.1941     Document Type: Article

References (33)

1. Acarin N, Rio J, Fernandez AL, Tintore M, Duran I, Galan I, et al. Different antiganglioside antibody pattern between relapsing remitting and progressive multiple sclerosis. Acta Neurol Scand 1996; 93: 99-103.
2. Charcot JM. Histologie de la sclerose en plaques. Gaz Hop (Paris). 1868; 41: 554-5, 557-8, 566.
3. Charcot JM. Lectures on the diseases of the nervous system. Translated by Sigerson G. London: The New Sydenham Society; 1877. p. 157-222.
4. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103: 281-300.
5. Cottrell DA, Kremenchutzky M, Rice GPA, Hader W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 6: applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain 1999a; 122: 641-7.
6. Cottrell DA, Kremenchutzky M, Rice GPA, Hader W, Koopman WJ, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 5: the clinical features and natural history of primary progressive multiple sclerosis. Brain 1999b; 122: 625-39.
7. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7.
8. Hader WJ, Elliot M, Ebers GC. Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, Canada. Neurology 1988; 38: 617-21.
9. Hillert J, Gronning M, Nyland H, Link H, Olerup O. An immunogenetic heterogeneity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1992; 55: 887-90.
10. Huber O. Zur pathologischen Anatomie der multiplen Sklerose des Rückenmarks. Virchows Arch Path Anat Physiol 1895; cxl: 396.
11. Lassmann H. Neuropathology in multiple sclerosis: new concepts. Mult Scier 1998: 4: 93-8.
12. Lublin FD, Reingold SC, for the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-11.
13. Madigand M, Oger JJ, Fauchet R, Sabouraud O, Genetet B. HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes. J Neurol Sci 1982; 53: 519-29.
14. McAlpine D, Compston ND, Lumsden CE. Multiple sclerosis. Edinburgh: Livingstone; 1955.
15. McAlpine D, Lumsden CE, Acheson ED. Multiple sclerosis: a reappraisal. Edinburgh; Livingstone: 1965.
16. Olerup O, Hillert J, Fredrikson S, Olsson T, Kam-Hansen S, Moller E, et al. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci USA 1989; 86: 7113-7.
17. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
18. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
19. Redlich E. Neuen Arbeiten (ber die Aetiologie und Pathologie der multiplen Sklerose. Zentralbl Allg Path Path Anat 1897; viii: 628.
20. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994; 117: 759-65.
21. Rice G, Ebers G. Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease? Arch Neurol 1998; 55: 1578-80.
22. Rose AS, Ellison GW, Myers LW, Tourtellotte WW. Criteria for the clinical diagnosis of multiple sclerosis. Neurology 1976; 26: 20-2.
23. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow up. Brain 1993; 116: 117-34.
24. Schumacher GA: Problems of experimental trials of therapy in multiple sclerosis. Report by the panel on evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965; 122: 552-68.
25. Thompson AJ, Kermode AG, MacManus DG, Kendall BE, Kingsley DP, Mosely IF. Patterns of disease activity in multiple sclerosis: a clinical and magnetic resonance imaging study [see comments]. BMJ 1990; 300: 631-4. Comment in: BMJ 1990; 300: 1272.
26. Thompson AJ, Kermode AG, MacManus DG, Kendall BE, Kingsley DP, Mosely IF. Patterns of disease activity in multiple sclerosis: a clinical and magnetic resonance imaging study [see comments]. BMJ 1990; 300: 631-4. Comment in: BMJ 1990; 300: 1272.
27. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple slerosis [see comments]. N Engl J Med 1998; 338: 278-85. Comment in: N Engl J Med 1998; 338: 323-5.
28. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple slerosis [see comments]. N Engl J Med 1998; 338: 278-85. Comment in: N Engl J Med 1998; 338: 323-5.
29. Van Lambalgen R, Sanders EA, D'Amaro, J. Sex distribution, age of onset and HLA profiles in two types of multiple sclerosis. J Neurol Sci 1986; 76: 13-21.
30. Weinshenker BG, Bass G, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis : a geographically based study. I. Clinical course and disability. Brain 1989a; 112: 133-46.
31. Weinshenker BG, Bass, B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989b; 112: 1419-28.
32. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991a; 114: 1045-56.
33. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991b; 1114: 1057-67.